250 Participants Needed

Psychological Intervention for Type 1 Diabetes

AF
HC
HS
Overseen ByHaley Sandoval
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Scripps Whittier Diabetes Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new psychological program called ACT1VATE, designed to assist people with type 1 diabetes who feel emotionally drained by their condition. The trial aims to determine if ACT1VATE can improve emotional well-being and blood sugar control more effectively than standard care, which involves diabetes self-management education and support (DSME/S). Individuals with type 1 diabetes who experience significant emotional stress related to their condition and have recently struggled with blood sugar control might be suitable for this trial. Participants will either try the new program or continue with usual care to compare results. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that ACT1VATE is a new psychological treatment designed to help people with type 1 diabetes who feel stressed about their condition. Although still under study, it aims to improve emotional well-being, which can aid in better diabetes management.

As a psychological treatment, ACT1VATE does not involve new medications or physical procedures, typically resulting in fewer risks of physical side effects. Psychological treatments like ACT1VATE are generally considered safe and well-tolerated by participants. However, as it remains in the middle stage of clinical trials, researchers are gathering more information to fully confirm its safety and effectiveness.

In summary, while ACT1VATE is still being tested, psychological treatments usually pose less risk compared to new drugs. Participants can expect a focus on emotional support, which might help in managing diabetes more effectively.12345

Why are researchers excited about this trial?

Researchers are excited about ACT1VATE because it offers a fresh approach to managing the emotional challenges of living with Type 1 diabetes. Unlike standard treatments that focus on diabetes self-management education and support (DSME/S), ACT1VATE is specifically designed to tackle diabetes-related emotional distress through psychological intervention. This approach could potentially enhance overall well-being and improve diabetes management by addressing the emotional hurdles that often accompany the condition.

What evidence suggests that this trial's treatments could be effective for type 1 diabetes?

Research shows that psychological treatments can help manage emotional stress in people with type 1 diabetes (T1D). In this trial, participants may receive ACT1VATE, a psychological intervention specifically designed to address diabetes-related emotional distress. Studies have found that reducing emotional stress can lead to better blood sugar control. Although specific data on ACT1VATE is limited, similar methods have improved both mental health and diabetes management. This suggests that ACT1VATE might help people feel better and manage their diabetes more effectively. Another group in this trial will receive DSME/S, the standard diabetes self-management education and support, to compare its effectiveness with ACT1VATE.12456

Who Is on the Research Team?

Dr. Athena Philis-Tsimikas ...

Athena Philis-Tsimikas, MD

Principal Investigator

Scripps Whittier Diabetes Institute

AF

Addie Fortmann, PhD

Principal Investigator

Scripps Whittier Diabetes Institute

Are You a Good Fit for This Trial?

This trial is for adults with Type 1 Diabetes who feel very stressed about their diabetes and have high blood sugar levels (HbA1c ≥ 8% in the last 90 days). They must speak English or Spanish, be a patient at Scripps Health, and plan to stay in San Diego for the next year. People with severe health or mental issues that could affect participation are not eligible.

Inclusion Criteria

Glycosylated Hemoglobin (HbA1c) between 7.5% and 12.5% in the last 90 days
I have been diagnosed with Type 1 diabetes.
Screen positive for diabetes distress

Exclusion Criteria

Severe medical or psychological conditions that would interfere with participation based on the opinion of a provider
Plans to move out of the San Diego area in the next 12 months
Lack of technology capability required to complete online surveys and telemedicine visit

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either the ACT1VATE psychological intervention or DSME/S usual care via telemedicine

5 sessions over 6 months
5 group-therapy sessions (virtual) for ACT1VATE group

Follow-up

Participants are monitored for changes in glycemic control and emotional distress

12 months
Quarterly standard-of-care medical visits

Process Evaluation

Evaluation of reach, acceptability, feasibility, adoption, maintenance, and fidelity of the intervention

12 months

What Are the Treatments Tested in This Trial?

Interventions

  • ACT1VATE
  • DSME/S
Trial Overview The study compares 'ACT1VATE', a psychological intervention aimed at reducing stress related to diabetes, against standard diabetes education and support (DSME/S) to see which is better at improving control of blood sugar levels and overall well-being among patients.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: ACT1VATEExperimental Treatment1 Intervention
Group II: DSME/S (usual care)Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Scripps Whittier Diabetes Institute

Lead Sponsor

Trials
19
Recruited
5,400+

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials
2,513
Recruited
4,366,000+

Published Research Related to This Trial

A study involving 305 U.S. adults with type 1 diabetes identified seven key sources of diabetes distress, including Powerlessness and Hypoglycemia Distress, which were confirmed in a separate sample of 109 Canadian participants.
The prevalence of diabetes distress was notably high, with 41.6% of participants experiencing at least moderate distress, particularly among women, younger individuals, and those with poor glycemic control, highlighting the need for targeted support in clinical care.
Understanding the sources of diabetes distress in adults with type 1 diabetes.Fisher, L., Polonsky, WH., Hessler, DM., et al.[2022]
Targeted interventions significantly reduced diabetes distress in adults with Type 1 diabetes, with an average decrease of 0.6 points in the intervention group compared to only 0.2 points in the untreated group, indicating the efficacy of the intervention.
Without treatment, over half (51%) of individuals with elevated diabetes distress continued to experience high levels of distress after 9 months, highlighting that untreated diabetes distress tends to remain chronic.
There is value in treating elevated levels of diabetes distress: the clinical impact of targeted interventions in adults with Type 1 diabetes.Hessler, D., Fisher, L., Polonsky, W., et al.[2022]
In a study involving 301 adults with type 1 diabetes, reductions in diabetes distress were linked to improved self-care behaviors, such as better insulin management and increased blood glucose monitoring, which are crucial for effective diabetes management.
The improvements in self-care behaviors subsequently led to better glycemic outcomes, including lower HbA1c levels and fewer hypoglycemic episodes, highlighting the importance of addressing diabetes distress to enhance overall diabetes care.
Reductions in Management Distress Following a Randomized Distress Intervention Are Associated With Improved Diabetes Behavioral and Glycemic Outcomes Over Time.Hessler, D., Strycker, L., Fisher, L.[2022]

Citations

1.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/39265782/
Protocol for ACT1VATE randomized controlled trial - PubMedThe purpose of this in-progress trial is to compare an ACT group intervention (ACT1VATE) with usual care in improving HbA1c, DD, quality of life, and cost- ...
ACT1VATE: Addressing Emotional Distress to Improve ...This research will compare a psychological intervention ("ACT1VATE") versus diabetes self-management education and support (DSME/S; usual care) in improving ...
Protocol for ACT1VATE randomized controlled trialThe purpose of this in-progress trial is to compare an ACT group intervention (ACT1VATE) with usual care in improving HbA1c, DD, quality of life, and cost- ...
ACT1VATE: Addressing Emotional Distress to Improve ...This research will compare a psychological intervention ("ACT1VATE") versus diabetes self-management education and support (DSME/S; usual care) ...
ACT1VATE: Addressing Emotional Distress to Improve ...This research will compare a psychological intervention ("ACT1VATE") versus diabetes self-management education and support (DSME/S; usual care) in improving ...
Protocol for ACT1VATE Randomized ControlledAs DD is highly prevalent, with an estimated 42% of adults with type 1 diabetes (T1D) reporting clinically significant DD (4), there have been efforts to ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security